Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.6600+0.1100 (+4.31%)
At close: 3:29PM EDT
Currency in CAD

Valuation measures

Market cap (intra-day) 537.89M
Enterprise value 310.04M
Trailing P/E N/A
Forward P/E 1-1.26
PEG Ratio (5 yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)1.35
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7-0.96

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-61.45%
S&P500 52-week change 335.11%
52-week high 37.7500
52-week low 32.5000
50-day moving average 33.1127
200-day moving average 34.3547

Share statistics

Avg vol (3-month) 36.72k
Avg vol (10-day) 320.66k
Shares outstanding 514.24M
Implied shares outstanding 6N/A
Float 12.45M
% held by insiders 110.53%
% held by institutions 13.59%
Shares short (30 Aug 2021) 48.72k
Short ratio (30 Aug 2021) 41.91
Short % of float (30 Aug 2021) 40.63%
Short % of shares outstanding (30 Aug 2021) 40.06%
Shares short (prior month 29 Jul 2021) 48.58k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -10.45M
Net income avi to common (ttm)-15.17M
Diluted EPS (ttm)-1.8210
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)36.08M
Total cash per share (mrq)2.53
Total debt (mrq)8.84M
Total debt/equity (mrq)32.10
Current ratio (mrq)45.15
Book value per share (mrq)1.98

Cash flow statement

Operating cash flow (ttm)-9.06M
Levered free cash flow (ttm)N/A